Influenza A antibody | 1331
Mouse anti Influenza A antibody, clone 1331, recognizes the nucleoprotein of Influenza A. It has been found reactive with over 50 isolates from H1 through to H14 and gives 'nuclear' staining in immunofluorescence.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Influenza virus from Texas strain.
- Approx. Protein Concentrations
- 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Shelf Life
- 18 months from date of despatch.
- P18072 Related reagents
- GO Terms
- GO:0003723 RNA binding
- GO:0030529 ribonucleoprotein complex
- GO:0005198 structural molecule activity
- GO:0019012 virion
- GO:0042025 host cell nucleus
- GO:0044419 interspecies interaction between organisms
- For research purposes only
Applications of Influenza A antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen||1/100||1/500|
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for Influenza A antibody
Leibbrandt, A. et al. (2010) Iota-carrageenan is a potent inhibitor of influenza A virus infection.
PLoS One. 5: e14320.
Nakayama, M. et al. (2016) Vaccination against H9N2 avian influenza virus reduces bronchus-associated lymphoid tissue formation in cynomolgus macaques after intranasal virus challenge infection.
Pathol Int. 66 (12): 678-86.